Literature DB >> 1965314

The growth hormone secretory response to fentanyl in rat: an involvement of mu type receptors.

J Govaerts1, P Buydens, E Finné, A Matton, L Vanhaelst.   

Abstract

Fentanyl, a selective mu opioid receptor agonist, administered intravenously, influences growth hormone secretion in conscious male rats. A dose-response study demonstrated that the maximum growth hormone release was obtained with 10 micrograms/kg while higher doses were less or not effective. MR-2266 (6 mg/kg i.v.), a mu and kappa opioid receptor antagonist, and bremazocine (0.1 mg/kg i.v.) a mu opioid receptor antagonist with kappa agonistic properties, both potently inhibited the growth hormone response to fentanyl (10 micrograms/kg i.v.). In contrast, the effect of fentanyl on growth hormone release was not blocked in rats treated with either ICI-154129 (30 mg/kg i.v. or 150 micrograms/kg intracerebroventricularly a selective delta opioid receptor antagonist, or U-50488 (10 mg/kg i.v.), a specific kappa opioid receptor agonist. These results suggest that opioid receptors of the mu type are involved in the fentanyl-induced growth hormone release.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1965314     DOI: 10.1007/bf03349653

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  24 in total

1.  A rapid and simple procedure for chronic cannulation of the rat jugular vein.

Authors:  P G Harms; S R Ojeda
Journal:  J Appl Physiol       Date:  1974-03       Impact factor: 3.531

2.  Mu opiate isoreceptors: differentiation with kappa agonists.

Authors:  P L Wood; J W Richard; M Thakur
Journal:  Life Sci       Date:  1982 Nov 15-22       Impact factor: 5.037

3.  Selective antagonists at the opiate delta-receptor.

Authors:  J S Shaw; L Miller; M J Turnbull; J J Gormley; J S Morley
Journal:  Life Sci       Date:  1982 Sep 20-27       Impact factor: 5.037

4.  Specific mu 2 opioid isoreceptor regulation of nigrostriatal neurons: in vivo evidence with naloxonazine.

Authors:  P L Wood; G W Pasternak
Journal:  Neurosci Lett       Date:  1983-06-30       Impact factor: 3.046

5.  Identification of multiple opiate receptors through neuroendocrine responses. I. Effects of agonists.

Authors:  R Pechnick; R George; R E Poland
Journal:  J Pharmacol Exp Ther       Date:  1985-01       Impact factor: 4.030

6.  Opioid kappa receptors and the secretion of prolactin (PRL) and growth hormone (GH) in the rat. II. GH and PRL release-inhibiting effects of the opioid kappa receptor agonists bremazocine and U-50,488.

Authors:  L Krulich; J I Koenig; S Conway; S M McCann; M A Mayfield
Journal:  Neuroendocrinology       Date:  1986       Impact factor: 4.914

7.  Opioid kappa receptors and the secretion of prolactin (PRL) and growth hormone (GH) in the rat. I. Effects of opioid kappa receptor agonists bremazocine and U-50,488 on secretion of PRL and GH: comparison with morphine.

Authors:  L Krulich; J I Koenig; S Conway; S M McCann; M A Mayfield
Journal:  Neuroendocrinology       Date:  1986       Impact factor: 4.914

8.  U-50,488: a selective and structurally novel non-Mu (kappa) opioid agonist.

Authors:  P F Vonvoigtlander; R A Lahti; J H Ludens
Journal:  J Pharmacol Exp Ther       Date:  1983-01       Impact factor: 4.030

9.  [3H]Sufentanil, a superior ligand for mu-opiate receptors: binding properties and regional distribution in rat brain and spinal cord.

Authors:  J E Leysen; W Gommeren; C J Niemegeers
Journal:  Eur J Pharmacol       Date:  1983-02-18       Impact factor: 4.432

10.  Long-acting opiate agonists and antagonists: 14-hydroxydihydromorphinone hydrazones.

Authors:  G W Pasternak; E F Hahn
Journal:  J Med Chem       Date:  1980-06       Impact factor: 7.446

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.